EDITORIAL

ACE inhibitors: back to prime time?

Milan Gupta¹, Subodh Verma², G B John Mancini³

¹ Division of Cardiology, William Osler Health Centre, McMaster University, Hamilton, Canada
² Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Toronto, Canada
³ Division of Cardiology, University of British Columbia, Vancouver, Canada

Correspondence to:
Correspondence to:
Dr S Verma
Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, Canada, M5B 1W8; subodh.verma{at}sympatico.ca

See articles on pages 1026 and 1081

Abbreviations: CV, cardiovascular; EMEA, European Medicines Evaluation Agency; FDA, Federal Drug Agency; MI, myocardial infarction

Keywords: cost–benefit analysis; hypertension; cardiovascular diseases; ACE inhibitors

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Andrew Briggs, Borislava Mihaylova, Mark Sculpher, Alistair Hall, Jane Wolstenholme, Maarten Simoons, Jaap Deckers, Roberto Ferrari, Willem J Remme, Michel Bertrand, Kim Fox on behalf of the EUROPA Trial Investigators
Heart 2007 93: 1081-1086. [Abstract] [Full Text] [PDF]

Renin: friend or foe?

Morris J Brown
Heart 2007 93: 1026-1033. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Henriksson, M, Epstein, D M, Palmer, S J, Sculpher, M J, Clayton, T C, Pocock, S J, Henderson, R A, Buxton, M J, Fox, K A A (2008). The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 94: 717-723 [Abstract] [Full Text]